Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: Rationale and design of the Studies of PCSK9 Inhibition and the Reduction of vascular E
scientific article published on 28 May 2016
Author/s
author: Wolfgang Koenig, Paul Ridker, Robert J Glynn, Steven Nissen, J Wouter Jukema, John J. P. Kastelein, Jean-Claude Tardif, Pierre Amarenco, James Revkin, Carla Yunis, Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Investigators
Work details
Copyright status
Copyright status information is not available for this work. The copyright status depends on the jurisdiction, the author's date of death and the date the work was created or published.
To learn more about copyright terms in different countries, visit the countries and terms page.